GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Strata Skin Sciences Inc (NAS:SSKN) » Definitions » Equity-to-Asset

Strata Skin Sciences (Strata Skin Sciences) Equity-to-Asset

: 0.30 (As of Dec. 2023)
View and export this data going back to 2005. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Strata Skin Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $12.69 Mil. Strata Skin Sciences's Total Assets for the quarter that ended in Dec. 2023 was $42.02 Mil. Therefore, Strata Skin Sciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.30.

The historical rank and industry rank for Strata Skin Sciences's Equity-to-Asset or its related term are showing as below:

SSKN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3   Med: 0.53   Max: 0.66
Current: 0.3

During the past 13 years, the highest Equity to Asset Ratio of Strata Skin Sciences was 0.66. The lowest was 0.30. And the median was 0.53.

SSKN's Equity-to-Asset is ranked worse than
85.17% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs SSKN: 0.30

Strata Skin Sciences Equity-to-Asset Historical Data

The historical data trend for Strata Skin Sciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strata Skin Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 0.55 0.55 0.42 0.30

Strata Skin Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.39 0.31 0.34 0.30

Competitive Comparison

For the Medical Devices subindustry, Strata Skin Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strata Skin Sciences Equity-to-Asset Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Strata Skin Sciences's Equity-to-Asset falls into.



Strata Skin Sciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Strata Skin Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=12.688/42.016
=0.30

Strata Skin Sciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=12.688/42.016
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Strata Skin Sciences  (NAS:SSKN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Strata Skin Sciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Strata Skin Sciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Strata Skin Sciences (Strata Skin Sciences) Business Description

Traded in Other Exchanges
Address
5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.
Executives
Shmuel Gov officer: SVP & General Manager Carlsbad 5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Samuel Rubinstein director 5 WALNUT GROVE DR., SUITE 140, HORSHAM PA 19044
Wayne Cafran director 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Irit Yaniv director 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
22nw Gp, Inc. 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw Fund Gp, Llc 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Aron R. English 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw, Lp 10 percent owner 590 1ST AVE S, UNIT C1, SEATTLE WA 98104
22nw Fund, Lp 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Christopher Lesovitz officer: Chief Financial Officer 5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Robert Joseph Moccia director, officer: Chief Executive Officer 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
William D. Humphries director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Patricia S Walker director 5540 EKWILL ST STE D, SANTA BARBARA CA 93111
Douglas Strang director 5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727